Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Liabilities (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Total Liabilities for 10 consecutive years, with $27.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 60.27% year-over-year to $27.7 million, compared with a TTM value of $27.7 million through Sep 2025, down 60.27%, and an annual FY2024 reading of $64.4 million, down 14.67% over the prior year.
  • Total Liabilities was $27.7 million for Q3 2025 at Spero Therapeutics, down from $29.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $83.4 million in Q1 2022 and bottomed at $24.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $50.4 million, with a median of $47.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 286.64% in 2021, then plummeted 60.27% in 2025.
  • Year by year, Total Liabilities stood at $82.8 million in 2021, then plummeted by 40.97% to $48.9 million in 2022, then soared by 54.49% to $75.5 million in 2023, then fell by 14.67% to $64.4 million in 2024, then plummeted by 57.04% to $27.7 million in 2025.
  • Business Quant data shows Total Liabilities for SPRO at $27.7 million in Q3 2025, $29.3 million in Q2 2025, and $43.9 million in Q1 2025.